Objectives To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib.
Design Population based retrospective cohort study.
Setting Databases of hospital discharge summaries and prescription drug claims in Quebec.
Participants 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or an NSAID after an index admission for congestive heart failure between April 2000 and March 2002.
Main outcome measures Time to all cause death and recurrent congestive heart failure, combined and separately.
Results The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib.
Conclusions Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.

中文翻译：

---

充血性心力衰竭患者使用塞来昔布，罗非昔布或非甾体类抗炎药的结局差异：基于人群的研究

目的比较塞洛昔布，罗非昔布或非甾体抗炎药（NSAIDs）老年患者的死亡和复发性充血性心力衰竭的风险，并确定塞来昔布和罗非昔布之间是否存在类别差异。
设计基于人群的回顾性队列研究。在魁北克
设置医院出院摘要和处方药索赔数据库。在2000年4月至2002年3月之间接受充血性心力衰竭指数入院后，
参与者2256名66岁或以上的患者开出了塞来昔布，罗非考昔或NSAID。
主要结局指标分别导致死亡和复发性充血性心力衰竭的时间，分别考虑。
结果处方NSAIDs或rofexocib的患者死亡和复发性充血性心力衰竭的合并风险高于塞来昔布的患者（危险比1.26、95％置信区间1.00至1.57和1.27、1.09至1.49）。当单独评估结局时，发现是相似的。在成对分析中，处方NSAIDs和罗非昔布治疗的患者死亡和复发性充血性心力衰竭的合并和分离风险相似。
结论对于老年充血性心力衰竭患者，塞来昔布似乎比罗非昔布和非甾体抗炎药更安全。发现在环氧合酶2抑制剂之间存在差异。